Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Medigen BiotechnologyROCO:3176 +2.31%58 PB Ratio is 3.18 as of Jul. 15, 2026, which is 4% below its 10-year median of 3.31. GuruFocus rates ROCO:3176 with a GF Score™ of 58/100 and a GF Value™ of NT$49.63 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 1,228 Biotechnology companies, Medigen Biotechnology ranks worse than 52.52% on this metric.
Medigen Biotechnology Corp stock PB Ratio (=3.43) is close to 2-year high of 3.6.
The historical rank and industry rank for Medigen Biotechnology's PB Ratio or its related term are showing as below:
ROCO:3176'
s PB Ratio Range Over the Past 10 Years
Min: 1.61 Med: 3.31 Max: 10.1
Current: 3.17
During the past 13 years, Medigen Biotechnology's highest PB Ratio was 10.10. The lowest was 1.61. And the median was 3.31.
ROCO:3176's PB Ratio is ranked worse than 52.52% of 1228
companies
in the Biotechnology industry
Industry Median: 2.895
vs ROCO:3176: 3.17
During the past 12 months, Medigen Biotechnology's average Book Value Per Share Growth Rate was -2.00% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -10.90% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -6.50% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was -2.60% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Medigen Biotechnology was 39.50% per year. The lowest was -14.90% per year. And the median was -0.50% per year.
Back to Basics: PB Ratio
Medigen Biotechnology (ROCO:3176) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:3176 vs VRTX, REGN, ALNY: PB Ratio Comparison
For the Biotechnology subindustry, Medigen Biotechnology's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medigen Biotechnology PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Medigen Biotechnology's PB Ratio distribution charts can be found below:
* The bar in red indicates where Medigen Biotechnology's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Medigen Biotechnology (ROCO:3176) has a PB Ratio of 3.18 as of Jul. 15, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Medigen Biotechnology and its competitors. This is near median its historical median of 3.31. Over the past decade, Medigen Biotechnology's PB Ratio has ranged from 1.61 to 10.10. According to the industry distribution chart, Medigen Biotechnology ranks #645 out of 1228 companies in the Biotechnology industry, placing it in the top 52.5%.
Is Medigen Biotechnology's PB Ratio too high?
Medigen Biotechnology's current PB Ratio of 3.18 is near median its 10-year median of 3.31. Over the past 10 years, this metric has ranged from a low of 1.61 to a high of 10.10. The Biotechnology industry median PB Ratio is 2.90. Medigen Biotechnology's value of 3.18 is 9.8% above this industry median. Based on the distribution chart, Medigen Biotechnology ranks #645 out of 1228 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Medigen Biotechnology has a GF Score™ of 58/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Medigen Biotechnology's PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Medigen Biotechnology ranks #645 out of 1228 companies for PB Ratio. This places Medigen Biotechnology in the lower half of its industry. The industry median PB Ratio is 2.90. Medigen Biotechnology's value of 3.18 is 9.8% above this benchmark. Historically, Medigen Biotechnology's own PB Ratio has ranged from 1.61 to 10.10 over the past decade. While the company's 10-year median is 3.31 vs. the industry median of 2.90, Medigen Biotechnology has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.90, based on 1,228 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medigen Biotechnology's current PB Ratio of 3.18 is 9.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Medigen Biotechnology and its competitors. For the Biotechnology industry, the median PB Ratio is 2.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medigen Biotechnology's current PB Ratio is 3.18, which is near median its own 10-year median of 3.31. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medigen Biotechnology stock overvalued right now?
Based on GuruFocus' analysis, Medigen Biotechnology (ROCO:3176) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$49.63, compared to a current price of NT$35.40 — trading 28.7% below its estimated fair value. The current PB Ratio is 3.18, which is near median its 10-year median of 3.31 and 9.8% above the Biotechnology industry median of 2.90. Medigen Biotechnology's overall GF Score™ is 58/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Medigen Biotechnology (ROCO:3176), the current PB Ratio is 3.18 as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medigen Biotechnology (ROCO:3176) Overvalued in 2026?
Based on GuruFocus' analysis, Medigen Biotechnology stock appears to be undervalued.
The current stock price of NT$35.40 is trading 28.7% below its estimated GF Value™ of NT$49.63.
GuruFocus considers Medigen Biotechnology to be Modestly Undervalued.
Key valuation signals for ROCO:3176:
PB Ratio: 3.18 (near median its 10-year median of 3.31)
GF Value™: NT$49.63 vs. price of NT$35.40 (28.7% below fair value)
Industry Position: 9.8% above the Biotechnology median (#645 of 1228)
No single metric tells the full story. See the ROCO:3176 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medigen Biotechnology Corp is engaged in the research and development of new drugs and vaccines, cytotherapy, nucleic acid testing, and the production and sales of generic drugs, aesthetic medicine products and vaccine-related products. Its segments are the Nucleic acid department, the New drug and vaccine research and development segment, the Cytotherapy department, and the Generic drug, aesthetic medicine product and dietary supplement segment: responsible for production and sales and relevant services of western medicine, aesthetic medicine product, and dietary supplement. The majority of revenue is derived from generic drugs, aesthetic medicine products, and the dietary supplement segment. Geographically, it operates in Taiwan, China, and Other countries with revenue from Taiwan.
58GF Score
Get the complete analysis for ROCO:3176
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:3176 has been successfully added to your 
